November 5, 2016. While quinolones can be life-saving drugs for certain types of infections, we must re-examine their safety and efficacy in light of new information to ensure the benefits outweigh the harms.
Read More »On Health Policy
NCHR’s Comment on USPSTF’s Draft Recommendation Statement for Child Maltreatment: Primary Care Interventions
June 18, 2018. Given the burden of child maltreatment on our society’s children, it is critical to continuously evaluate any new evidence to find effective interventions that can prevent child maltreatment.
Read More »NCHR Comments on FDA’s Draft Guidance on Inclusion of Pregnant Women in Clinical Trials
June 8, 2018. We commend the FDA in its efforts to provide guidance on the inclusion of pregnant women in clinical trials. Currently, there is limited information regarding benefits and risks of drugs in pregnant women, including potential benefits and risks to the fetus.
Read More »NCHR Co-Signs Letter of Support for Patient Advocacy Transparency Act
March 8, 2018 The Honorable Claire McCaskill United States Senate 503 Hart Senate Office Building Washington, DC, 20510 Dear Senator McCaskill: We welcome the Patient Advocacy Transparency Act, which will expand the Physician Payments Sunshine Act to include disclosure of pharmaceutical and medical device company payments to advocacy organizations, professional societies, and other third parties. […]
Read More »NCHR Comment on USPSTF’s Draft Recommendation Statement Screening for Intimate Partner Violence and Elder Abuse
May 21, 2018. In conclusion, we agree with the USPSTF’s efforts to provide updated recommendations on screening of IPV and abuse based on quality, up-to-date studies. The benefits of screening for IPV for women outweigh the risks, and future studies should allow recommendations to be made for other populations. We agree with the USPSTF draft recommendation on IPV and elder abuse.
Read More »